Abstract
Short-chain fatty acids (SCFAs), particularly butyrate, are central microbial metabolites with local epithelial actions and increasingly recognized neuroactive signaling roles along the microbiota–gut–brain axis [1–4]. However, oral delivery of free butyrate salts (e.g., sodium butyrate) faces dual challenges: (i) premature dissolution and absorption in the upper gastrointestinal tract—reducing availability to distal intestinal and colonic sensing circuits [5–7], and (ii) organoleptic issues (rancid butter-like odor/taste) undermining long-term adherence [5–7]. Evidence suggests pH-responsive enteric polymer coatings and microencapsulation technologies can protect butyrate payloads against gastric conditions, delay proximal absorption, and improve acceptability by isolating volatile odorants [7–9]. Distal gut-targeted SCFA exposure is mechanistically tied to vagal nerve stimulation (VNS), including SCFA receptor-dependent afferent firing, brainstem activation, and indirect endocrine transduction via L-cell GLP-1/PYY and enterochromaffin serotonin pathways [3, 10–12]. Thus, for neurogastroenterology and gut–brain therapeutics, formulation—not molecule selection alone—determines efficacy and tolerability of butyrate interventions [7, 9].
Introduction
SCFAs—acetate, propionate, and butyrate—are microbial metabolites produced in the lower gut via bacterial fermentation of dietary fibers [1, 13]. These metabolites form a key communication link in the gut–brain axis, engaging neural, endocrine, immune, and metabolic pathways [14–16]. In humans, SCFAs appear in the colon at approximate molar ratios of 60:20:20 [13, 16].
Unique role of butyrate
Butyrate is a preferred fuel for colonocytes, supporting epithelial integrity and inflammation control [2, 17, 18]. It acts as a ligand for GPCRs such as FFAR2 (GPR43), FFAR3 (GPR41), and GPR109a/HCAR2, while also inhibiting histone deacetylases (HDACs), leading to epigenetic and anti-inflammatory effects [13, 15, 21].
Formulation challenges
Butyrate's biological targets (e.g., colonic epithelium, distal L-cells, vagal afferents) are predominantly distal. However, free butyrate salts often dissolve early and appear rapidly in peripheral blood, altering their physiological impact [5, 11]. Effective formulations must delay release to engage distal gut receptors and neural circuits [5, 22, 23].
Pharmacology and Pharmacokinetics
Butyrate metabolism
Butyrate supports gut health by serving as an energy substrate for colonocytes, driving mitochondrial oxidative metabolism [18, 26]. Colonocyte suspensions exposed to 10 mM butyrate utilized over 70% of oxygen consumption for butyrate oxidation [17]. Approximately 80–95% of SCFAs produced by bacteria are absorbed by the colon, with minimal concentrations left in feces [17].
Molecular properties and absorption
Butyrate's weak-acid character favors dissociation at colonic pH (5.0–6.5), enabling passive and carrier-mediated uptake via transporters such as MCT1/SLC16A1 and SMCT1/SLC5A8 [20, 26, 27]. Additional transport machinery like MCT4/MCT5 and apical efflux pump ABCG2 also play roles in intestinal epithelial handling [27].
First-pass utilization
Rapid utilization occurs in the gut–liver axis, with absorbed butyrate largely metabolized in intestinal cells and liver. A human study found only ~2% of ingested butyrate entered portal circulation, highlighting its local metabolic prioritization [26, 2]. These findings suggest systemic measurements may underrepresent luminal and epithelial effects, especially for distal-targeted formulations [2, 26].
Receptor and epigenetic pharmacology
Butyrate engages GPCRs and acts as an HDAC inhibitor, modulating gene expression, inflammation, and neural pathways [2, 21]. Mechanisms include upregulation of the μ-opioid receptor and inhibition of cAMP signaling through FFAR2 and FFAR3, affecting HDAC activity and immune/neural responses [19, 21].
Formulation-Dependent Pharmacokinetics
Prodrug strategies
Prodrug approaches, such as tributyrin (a butyrate triglyceride), delay release and reduce proximal absorption. Comparisons demonstrate esterified formulations can minimize gastric release while optimizing distal delivery [26, 21]. However, not all prodrug strategies equally delay release, highlighting the role of formulation chemistry [21].
Challenges of premature absorption
Rapid passive absorption in the stomach limits butyrate's delivery to distal sites. Immediate-release formulations may fail to signal colonic mucosal receptors or enteric/vagal circuits [5, 7]. Clinical studies reveal insufficient distal delivery due to early absorption and metabolism [2, 7].
Overcoming organoleptic barriers
The unpleasant sensory characteristics of butyrate (rancid odor/taste) reduce patient compliance in chronic regimens [7]. Strategies like enteric coatings and microencapsulation help mask odor and taste while enabling controlled release [7, 25]. These improvements align pharmacokinetic optimization with adherence goals [24].
Enteric Coating Technology
Polymer coatings
Enteric polymers like Eudragit® S100 (pH threshold 7.2) are widely used to protect drug cores from gastric acidity while enabling colonic release [8]. Combination coatings (e.g., Eudragit® L100 and S100) can broaden dissolution profiles, addressing inter-individual variability in GI pH [35].
Challenges and hybrid solutions
GI pH variability can limit the precision of pH-triggered coatings [9]. Hybrid systems combining pH- and time-dependent polymers may enhance reliability across diverse physiological conditions [9, 34]. Such approaches improve targeted release while mitigating inconsistencies caused by local pH shifts [35, 36].
Microencapsulation Approaches
Benefits of microencapsulation
Microencapsulation addresses premature release and organoleptic barriers. It allows controlled release in the distal gut and masks unpleasant taste and odor [7, 24].
Innovative delivery systems
- Protected sodium butyrate: Encapsulation in lipid microbeads or gel capsules enables delayed release and better palatability [6, 7].
- Controlled-release beads: Mechanistic studies using protected beads show reduced gastric release and delayed intestinal absorption [37, 38].
Future directions
Further optimization of polymer matrices and microcapsule technologies could improve distal delivery while enhancing compliance. Combining controlled and pH-responsive mechanisms represents a promising strategy for SCFA therapeutics targeting gut–brain signaling pathways [35, 36].
Lipid Matrices as Protective Barriers
Lipid matrices are commonly utilized as protective barriers. A study on diet-induced obese rats noted that microencapsulation in lipid matrices was developed to protect SCFAs from proximal intestinal digestion and target their release to the large intestine [22]. This approach explicitly contrasts microencapsulated products, which are designed to release SCFAs slowly in the lower gastrointestinal (GI) tract, with non-encapsulated sodium butyrate [22]. In a chicken infection model, microencapsulated sodium butyrate—coated with a "polymer enteral material" and containing 40% sodium butyrate—was shown to delay intestinal release, reduce small intestinal absorption, and enhance colonic delivery. The study also reported a higher effectiveness compared to non-encapsulated sodium butyrate administered at the same supplemental amount [28].
Polymeric Prodrug Micelles as an Alternative to Classical Enteric Coatings
An innovative approach employs butyrate-prodrug polymeric micelles. In this strategy, butyrate is attached to a micelle-forming polymer chain via ester bonds, allowing hydrolysis by digestive esterases and controlled release in the GI tract [25]. The authors validated this approach by testing the release in simulated gastric and intestinal fluids. They found negligible butyrate release in simulated gastric fluid over several hours but observed sustained slow release over weeks. In contrast, in simulated intestinal fluid with high pancreatin esterase concentration, the micelles released most of their butyrate within minutes [25]. According to the authors, these polymer formulations release butyrate in specific segments of the lower GI tract, unlike sodium butyrate, which is mainly absorbed in the stomach [25]. Additionally, they emphasize that polymer formulations mask butyrate's smell and taste and serve as carriers for time-controlled release as micelles traverse the GI tract [25].
Capsule Shell Approaches and Delayed Release Systems
Delayed release can also be achieved using specific capsule-shell or capsule-in-capsule technologies. An in vitro evaluation of targeted-release capsules for pancreatin protection highlighted that DRcaps®, composed of hydroxypropyl methylcellulose (HPMC) and gellan gum, supports delayed release in the small intestine [39]. Adding gellan gum improves HPMC's resistance against breakdown in the low-pH stomach environment, allowing intact capsules to reach the intestines [39]. While this study focuses on pancreatin and butyrate generation from tributyrin as a secondary effect, it provides evidence that selecting appropriate capsule-shell materials can prevent early disintegration in the stomach and ensure payload integrity until delivery to desired sites [39].
Comparison Table
The table below synthesizes protected-delivery strategies described in the supplied sources, emphasizing the following aspects: targeted regions, evidence of gastric resistance, and their implications for acceptability.
Vagal Nerve Stimulation Mechanisms
Evidence supports the hypothesis that short-chain fatty acids (SCFAs) can activate afferent neural pathways and induce downstream central neural activation. A broad review states that SCFAs directly activate the vagus nerve and outlines examples, such as butyrate increasing the firing rate of vagal afferent neurons communicating signals from the gut to the brain [3]. This review also discusses the role of FFAR3, which is expressed on vagal afferents originating from the gut. Vagal-FFAR3 knockout models exhibit altered feeding behavior and attenuated appetite suppression by propionate, offering further mechanistic insights [3]. Consistent with this, other reviews position SCFAs as neuroactive metabolites integral to microbiota–gut–brain communication via vagal, endocrine (GLP-1/PYY), and immune pathways [16, 40].
Direct Receptor-Linked Afferent Activation
High-resolution chemogenetic and physiological studies provide evidence on how colonic SCFA receptors drive gut–brain signaling. For instance, perfusion of colonic tissue with propionate (C3) induced a significant increase in nerve firing rate in ex vivo experiments [10]. The same study showed that sensory signaling originating in the proximal colon is transmitted to the nodose ganglia via the vagus nerve, with FFA3-selective activators (such as TUG-1907) increasing nerve activity in wild-type but not in FFA3 knockout tissue [10]. Furthermore, rectal or colonic exposure to propionate resulted in a higher number of c-Fos-positive neurons, which indicates central neural activation [10]. These findings strongly support a mechanistic framework for an SCFA–gut–brain axis mediated by colonic FFA2/FFA3 activation [10].
Indirect Endocrine Signaling via L-Cells
Another key mechanism for SCFA modulation of gut–brain communication involves endocrine signaling through enteroendocrine L-cells. L-cells, which are primarily located in the distal gastrointestinal tract, release GLP-1 and PYY in response to SCFAs [11]. One study noted that activation of FFAR2 on these cells mediates the secretion of these hormones, which are pivotal for central appetite regulation [11]. Moreover, butyrate has been found to promote differentiation of enteroendocrine cells toward a PYY-biased phenotype through a FFAR2–Gi axis, potentially enhancing endocrine signaling capacity upon chronic or repeated butyrate exposure [42].
Serotonin-Mediated Vagal Signaling
A third route involves serotonin signaling via enterochromaffin cells. SCFAs, particularly butyrate, stimulate Tph1 expression in these cells, thereby increasing serotonin (5-HT) production [12]. Released 5-HT can activate 5-HT3 receptors on afferent fibers of the vagus nerve, leading to downstream signaling through the nodose ganglion and potentially influencing central neural pathways [12]. This mechanism underscores the ability of distal SCFA exposure to affect vagal signaling through mediator release rather than direct action on vagal terminals [12].
Evidence for Necessity of Intact Vagal Pathways
In in vivo studies, the impact of SCFAs on vagal pathways has been demonstrated to depend on the integrity of these neural circuits. For example, one mouse study showed that oral butyrate decreased food intake and reduced neuronal activity markers in the brainstem's nuclei; this effect was abolished after subdiaphragmatic vagotomy, emphasizing the necessity of an intact gut–brain neural circuit [45]. Similarly, in a rat myocardial ischemia/reperfusion model, oral butyrate’s protective effects were diminished following vagotomy [46]. Together, these studies underscore the importance of distal delivery strategies for engaging vagus-dependent physiological pathways.
Microbial Metabolite Interoception via Small Intestine
While colonic targeting is crucial, small-intestinal delivery of SCFAs has also been shown to influence vagal activity. For instance, intestinal perfusion of SCFAs in a small intestinal model induced gradual increases in vagal afferent nerve activity [47]. This effect was inhibited by an FFAR2 antagonist [47]. Another study showed that microbial metabolites instigated neuronal c-Fos expression in the NTS at levels comparable to sucrose [48]. These findings highlight the potential for small-intestinal SCFA delivery to elicit vagal signaling, albeit with potential latencies compared to colonic delivery [47, 48].
Translational and Clinical Evidence
Human Pharmacokinetics and Formulation Effects
Human studies support the role of formulation in controlling SCFA delivery. It was observed that serum concentrations of orally ingested SCFAs peaked rapidly, returning to baseline after two hours, unless delivered using acid-resistant encapsulation, which delayed and blunted systemic exposure levels [5]. Another trial comparing sodium butyrate, lysine butyrate, and tributyrin emphasized that enzymatic release mechanisms result in slower but prolonged SCFA availability, depending on the formulation [26]. These results underscore the influence of formulation on SCFA absorption kinetics and its implications for targeted delivery [5, 26].
Microencapsulated Sodium Butyrate in GI Disorders
Studies also highlight the clinical potential of microencapsulated sodium butyrate in conditions like ulcerative colitis (UC) and inflammatory bowel disease (IBD). A prospective study on UC remission patients receiving microencapsulated butyrate reported improved outcomes, including lower fecal calprotectin levels and higher subjective quality of life scores compared to untreated controls [38]. A randomized trial using Butyrose® Lsc Microcaps in IBD demonstrated microbiota modulation and improved quality of life, although effects on clinical endpoints were heterogeneous, illustrating the need for patient-specific approaches [49].
Diverticular Disease and Butyrate Derivatives
In a placebo-controlled study in patients with diverticulosis, those receiving 300 mg sodium butyrate experienced significantly fewer diverticulitis episodes over 12 months compared to controls [24]. Additionally, a microencapsulated tributyrin formulation (BUTYCAPS) has been highlighted for its ability to provide controlled butyrate release and enhance compliance due to its once-daily dosing and reduced odor [24].
Metabolic and Brain-Related Translational Signals
Animal studies suggest chronic sodium butyrate intake alters brain glucose metabolism, enhances neurogenesis, and increases hippocampal cell volume [2]. These findings support the potential implications of enteric-coated and distal-targeted formulations to engage gut-derived endocrine and vagal pathways for systemic and central effects [2, 11].
Commercial Formulation Context
Commercial products emphasize the significance of odor masking and anatomical targeting through specialized coatings. For example, enteric-coated softgels with pectin and sodium alginate aim to ensure survival in the stomach and controlled release in the colon [51]. Proprietary microencapsulation approaches to trap volatile compounds have been implemented to improve tolerability and compliance while ensuring efficacious delivery to intestinal regions [52, 53].
Conclusion
A consensus across academic and commercial sources highlights that the benefits of butyrate for gut–brain axis modulation rely on precision delivery to the appropriate gastrointestinal sites. Enteric coatings, polymeric micelles, microencapsulation, and other advanced strategies offer promising tools to overcome SCFA’s chemical instability, odor, and taste challenges while enabling targeted release in the distal intestine [8, 25, 37, 39]. Emerging mechanistic data supporting vagal and endocrine pathways furthers the case for harnessing butyrate’s therapeutic potential through tailored formulations for both scientific and consumer applications [6, 10–12].
Translational Implications of Enteric-Targeted SCFAs
The translational implication is that “enteric-targeted SCFAs” should be conceptualized as a formulation class rather than a single ingredient. The most defensible engineering goal, supported by the supplied sources, is to design delivery systems that:
- Remain intact under acidic gastric conditions,
- Resist premature small-intestinal release under variable pH,
- Release butyrate in distal segments where receptor-mediated gut–brain signaling can occur,
- Provide robust odor/taste masking sufficient for long-term adherence [9, 25, 34].
